Overview Dividends

(LH) Laboratory of America - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5049221055

Diagnostics,Laboratory,Testing,Services

LH EPS (Earnings per Share)

EPS Growth (3Y CAGR): 0.35%
EPS Trend (3Y Correlation): 24.2%

LH Revenue

Revenue Growth (3Y CAGR): -1.11%
Revenue Trend (3Y Correlation): 44.4%

Risk via 10d forecast
Volatility	22.4%
Value at Risk 5%th	35.2%
Relative Tail Risk	-4.70%

Reward TTM
Sharpe Ratio	0.33
Alpha	0.48

Character TTM
Hurst Exponent	0.526
Beta	0.599
Beta Downside	0.610

Drawdowns 3y
Max DD	17.36%
Mean DD	6.00%
Median DD	5.17%

Description: LH Laboratory of America October 14, 2025

Labcorp (NYSE: LH) operates two primary segments-Diagnostics Laboratories and Biopharma Laboratory Services-delivering a broad menu of clinical tests ranging from routine blood chemistry and urinalysis to high-complexity gene-based and esoteric assays, as well as specialty services in oncology, cardiovascular disease, pharmacogenetics, and occupational health.

The firm’s client base spans pharmaceutical and biotech firms, medical-device manufacturers, managed-care organizations, hospitals, government agencies, and individual consumers, with additional revenue streams from specimen-collection logistics, digital patient/provider portals, and companion-diagnostic development for drug pipelines.

Key performance indicators (KPIs) from Labcorp’s FY 2023 results show total revenue of approximately $13.9 billion, a 5 % year-over-year increase driven largely by growth in specialty testing and biopharma services; operating margin expanded to 11 % as the company leveraged automation and scale efficiencies. The segment’s outlook is closely tied to macro drivers such as an aging U.S. population, rising prevalence of chronic diseases, and the shift toward value-based reimbursement models that favor high-volume, high-margin molecular diagnostics.

For analysts seeking a deeper, data-driven view of Labcorp’s valuation dynamics, a quick look at ValueRay’s proprietary model can surface hidden sensitivities and scenario analyses that are not captured in standard consensus estimates.

LH Stock Overview

Market Cap in USD	20,918m
Sub-Industry	Health Care Services
IPO / Inception	1990-03-29
Return 12m vs S&P 500	-2.18%
Analyst Rating	4.45 of 5

LH Dividends

Dividend Yield	1.35%
Yield on Cost 5y	2.14%
Yield CAGR 5y	24.57%
Payout Consistency	17.4%
Payout Ratio	18.2%

LH Growth Ratios

CAGR 3y	11.90%
CAGR/Max DD Calmar Ratio	0.69
CAGR/Mean DD Pain Ratio	1.98
Current Volume	1147.9k
Average Volume	1147.9k

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (855.2m TTM) > 0 and > 6% of Revenue (6% = 825.9m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 3.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 10.53% (prev 11.78%; Δ -1.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 1.80b > Net Income 855.2m (YES >=105%, WARN >=100%)

Net Debt (5.93b) to EBITDA (2.01b) ratio: 2.95 <= 3.0 (WARN <= 3.5)

Current Ratio 1.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (83.7m) change vs 12m ago -0.83% (target <= -2.0% for YES)

Gross Margin 28.45% (prev 27.92%; Δ 0.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 74.66% (prev 68.30%; Δ 6.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.73 (EBITDA TTM 2.01b / Interest Expense TTM 232.5m) >= 6 (WARN >= 3)

Altman Z'' 3.51

(A) 0.08 = (Total Current Assets 4.08b - Total Current Liabilities 2.63b) / Total Assets 18.26b

(B) 0.48 = Retained Earnings (Balance) 8.70b / Total Assets 18.26b

(D) 0.91 = Book Value of Equity 8.66b / Total Liabilities 9.55b

Total Rating: 3.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.14

1. Piotroski 9.0pt = 4.0

2. FCF Yield 5.14% = 2.57

3. FCF Margin 10.03% = 2.51

4. Debt/Equity 0.75 = 2.23

5. Debt/Ebitda 2.95 = -1.69

6. ROIC - WACC (= 0.91)% = 1.14

7. RoE 10.20% = 0.85

8. Rev. Trend 44.37% = 3.33

9. EPS Trend 24.17% = 1.21

What is the price of LH shares?

As of November 17, 2025, the stock is trading at USD 266.89 with a total of 1,147,902 shares traded.
Over the past week, the price has changed by +2.21%, over one month by -5.93%, over three months by -1.08% and over the past year by +13.11%.

Is Laboratory of America a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Laboratory of America (NYSE:LH) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 66.14 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LH is around 262.33 USD . This means that LH is currently overvalued and has a potential downside of -1.71%.

Is LH a buy, sell or hold?

Laboratory of America has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LH.

Strong Buy: 13
Buy: 3
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the LH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	299.1	12.1%
Analysts Target Price	299.1	12.1%
ValueRay Target Price	287	7.5%

LH Fundamental Data Overview November 06, 2025

Market Cap USD = 20.92b (20.92b USD * 1.0 USD.USD)
P/E Trailing = 24.7625
P/E Forward = 15.7978
P/S = 1.5196
P/B = 2.7407
P/EG = 0.9454
Beta = 0.966
Revenue TTM = 13.77b USD
EBIT TTM = 1.33b USD
EBITDA TTM = 2.01b USD
Long Term Debt = 5.33b USD (from longTermDebt, last fiscal year)
Short Term Debt = 691.1m USD (from shortTermDebt, last quarter)
Debt = 6.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.93b USD (from netDebt column, last quarter)
Enterprise Value = 26.85b USD (20.92b + Debt 6.53b - CCE 598.1m)
Interest Coverage Ratio = 5.73 (Ebit TTM 1.33b / Interest Expense TTM 232.5m)
FCF Yield = 5.14% (FCF TTM 1.38b / Enterprise Value 26.85b)
FCF Margin = 10.03% (FCF TTM 1.38b / Revenue TTM 13.77b)
Net Margin = 6.21% (Net Income TTM 855.2m / Revenue TTM 13.77b)
Gross Margin = 28.45% ((Revenue TTM 13.77b - Cost of Revenue TTM 9.85b) / Revenue TTM)
Gross Margin QoQ = 28.77% (prev 29.66%)
Tobins Q-Ratio = 1.47 (Enterprise Value 26.85b / Total Assets 18.26b)
Interest Expense / Debt = 0.86% (Interest Expense 56.0m / Debt 6.53b)
Taxrate = 22.40% (75.5m / 337.0m)
NOPAT = 1.03b (EBIT 1.33b * (1 - 22.40%))
Current Ratio = 1.55 (Total Current Assets 4.08b / Total Current Liabilities 2.63b)
Debt / Equity = 0.75 (Debt 6.53b / totalStockholderEquity, last quarter 8.70b)
Debt / EBITDA = 2.95 (Net Debt 5.93b / EBITDA 2.01b)
Debt / FCF = 4.30 (Net Debt 5.93b / FCF TTM 1.38b)
Total Stockholder Equity = 8.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.68% (Net Income 855.2m / Total Assets 18.26b)
RoE = 10.20% (Net Income TTM 855.2m / Total Stockholder Equity 8.38b)
RoCE = 9.72% (EBIT 1.33b / Capital Employed (Equity 8.38b + L.T.Debt 5.33b))
RoIC = 7.34% (NOPAT 1.03b / Invested Capital 14.10b)
WACC = 6.42% (E(20.92b)/V(27.45b) * Re(8.22%) + D(6.53b)/V(27.45b) * Rd(0.86%) * (1-Tc(0.22)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.71%
[DCF Debug] Terminal Value 73.42% ; FCFE base≈1.17b ; Y1≈911.1m ; Y5≈590.4m
Fair Price DCF = 128.9 (DCF Value 10.69b / Shares Outstanding 82.9m; 5y FCF grow -26.04% → 3.0% )
EPS Correlation: 24.17 | EPS CAGR: 0.35% | SUE: 0.98 | # QB: 3
Revenue Correlation: 44.37 | Revenue CAGR: -1.11% | SUE: 0.09 | # QB: 0

Additional Sources for LH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle